

1 **In vitro evidence against productive SARS-CoV-2 infection of human testicular**
2 **cells: Bystander effects of infection mediate testicular injury.**

3 Stefanos Giannakopoulos¹, Daniel P Strange², Boonyanudh Jiyarom², Omar
4 Abdelaal³, Aaron W Bradshaw^{3,4}, Vivek R Nerurkar², Monika A Ward⁵, Jackson Bakse⁵,
5 Jonathan Yap⁶, Selena Vanapruks⁶, William Boisvert⁶, Michelle D Tallquist¹, Cecilia
6 Shikuma², Hooman Sadri-Ardekani^{3,4}, Philip Clapp³, Sean Murphy³, Saguna Verma^{1,2#}.

7

8 ¹Department of Cell and Molecular Biology, John A. Burns School of Medicine, University
9 of Hawaii at Manoa, Honolulu, Hawaii, USA

10 ²Department of Tropical Medicine, Medical Microbiology, and Pharmacology, John A.
11 Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA

12 ³Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine,
13 Winston-Salem, North Carolina

14 ⁴Department of Urology, Wake Forest School of Medicine, Winston-Salem, North
15 Carolina

16 ⁵Institute for Biogenesis Research, John A Burns School of Medicine, University of Hawaii
17 at Manoa, Honolulu, Hawaii, USA

18 ⁶Center for Cardiovascular Research, John A. Burns School of Medicine, University of
19 Hawaii at Manoa, Honolulu, Hawaii, USA

20

21 **Running Title:** SARS-CoV-2 infection-derived mediators mediate testicular injury

22 #Corresponding author: Saguna Verma

23 E-mail: saguna@hawaii.edu

24 **Abstract**

25 The hallmark of severe COVID-19 involves systemic cytokine storm and multi-organ
26 failure including testicular injury and germ cell depletion. The ACE2 receptor is also
27 expressed in the resident testicular cells however, SARS-CoV-2 infection and
28 mechanisms of testicular injury are not fully understood. The testicular injury can likely
29 result either from direct virus infection of resident cells or by exposure to systemic
30 inflammatory mediators or virus antigens. We here characterized SARS-CoV-2 infection
31 in different human testicular 2D and 3D models including primary Sertoli cells, Leydig
32 cells, mixed seminiferous tubule cells (STC), and 3D human testicular organoids (HTO).
33 Data shows that SARS-CoV-2 does not establish a productive infection in any testicular
34 cell types. However, exposure of STC and HTO to inflammatory supernatant from infected
35 airway epithelial cells and COVID-19 plasma depicted a significant decrease in cell
36 viability and death of undifferentiated spermatogonia. Further, exposure to only SARS-
37 CoV-2 envelope protein, but not Spike or nucleocapsid proteins led to cytopathic effects
38 on testicular cells that was dependent on the TLR2 receptor. A similar trend was observed
39 in the K18h-ACE2 mouse model which revealed gross pathology in the absence of virus
40 replication in the testis. Collectively, data strongly indicates that the testicular injury is not
41 due to direct infection of SARS-CoV-2 but more likely an indirect effect of exposure to
42 systemic inflammation or SARS-CoV-2 antigens. Data also provide novel insights into the
43 mechanism of testicular injury and could explain the clinical manifestation of testicular
44 symptoms associated with severe COVID-19.

45

46

47 **Introduction:**

48 SARS coronavirus 2 (SARS-CoV-2), a positive-sense RNA virus, emerged in China in
49 December 2019 and has since evolved into different variants and spread across the globe
50 causing mild to severe coronavirus disease known as COVID-19. SARS-CoV-2 infects
51 susceptible human cells by binding to Angiotensin-Converting Enzyme 2 (ACE2) and
52 causes a range of clinical symptoms, which can progress to severe COVID-19 based on
53 vaccination status and co-morbidities (1, 2). In addition to the acute lung injury with diffuse
54 alveolar damage, other hallmarks of severe COVID-19 include multi-organ injury including
55 vascular inflammation, cardiac complications, and kidney failure (3, 4). Epidemiological
56 studies suggest that males irrespective of age and co-morbid conditions are
57 disproportionately affected and present a higher case-to-fatality ratio than females (5).

58
59 Recent pathological and clinical findings provide evidence that a large percentage of
60 males with COVID-19 report mild orchitis (inflammation of the testis associated with pain
61 and discomfort) as one of the symptoms (6). Further, postmortem analysis of testis from
62 COVID-19 patients display signs of mild to severe testicular pathology, including testicular
63 swelling, tubular injury, germ cell and LC depletion, and leukocyte infiltration in the
64 interstitium (5, 7, 8). In addition, alterations in the male fertility parameters like reduced
65 sperm count, reduced testosterone levels, and dysregulated ratio of testosterone to LH
66 (T/LH) have been reported in COVID-19 patients (9, 10). However, while the virus has
67 not been detected in the semen in several studies (11, 12), one study reported the
68 presence of low levels of SARS-CoV-2 RNA in the semen of 4/15 of patients at the acute
69 stage of infection and in 2/23 patients who were recovering from COVID-19 (13). Although

70 the presence of viral RNA is not direct evidence of productive infection of SARS-CoV-2
71 in the testis, and the ability of the virus to gain access to the testis may be a rare event,
72 these data do suggest that testicular injury is one of the complications of COVID-19.

73
74 SARS-CoV-2 viral replication and pathogenesis in extra-pulmonary organs are currently
75 not well understood. Emerging data demonstrate the presence of low-level viral RNA and
76 virus-like particles (VLPs) in many organs like the heart, kidney, testis, intestine, and brain
77 (8, 14–16). SARS-CoV-2 VLPs, comprised of all major structural proteins including Spike
78 (S), Nucleocapsid (N), Membrane (M), and Envelope (E), are abundantly secreted by the
79 infected cells and can enter cells just like SARS-CoV-2 infectious virions (17). In addition,
80 more recent studies detected SARS-CoV-2 proteins like S, N, and open reading frame 8
81 (ORF8) in the plasma of infected individuals illustrating antigenemia as one of the
82 hallmarks of SARS-CoV-2 infection (18, 19). Exposure of both S and N proteins induced
83 pro-inflammatory cytokines including interleukin 6 (IL-6) and tumor necrosis factor-alpha
84 (TNF- α) in human macrophages (20, 21). It is not known if the E protein is also secreted
85 in the bloodstream, but it is shown to form cation channels in the lipid bilayer and trigger
86 the hyperinflammatory response in human macrophages and mice (22). While specific
87 mechanisms by which SARS-CoV-2 cause testicular injury are still being characterized,
88 the cytokine storm is considered to be the main driving factor of damage to organs other
89 than lungs in severe COVID-19 patients (23). The testicular inflammation can likely result
90 either from direct virus infection of target cells or by exposure to systemic inflammatory
91 mediators or virus antigens.

92

93 In humans, testis show a very high level of constitutive gene expression of angiotensin
94 converting enzyme 2 (ACE2) that regulates testosterone production and interstitial fluid
95 volume via modulating conversion of Angiotensin II to Angiotensin I (24, 25). The single-
96 cell RNA-sequencing datasets from human testes revealed high expression of ACE2 in
97 undifferentiated spermatogonia including spermatogonia stem cells (SSC), Leydig (LC),
98 and Sertoli cells (SC) (26). However, although transmembrane serine protease 2
99 (TMPRSS2) is expressed in most of the cell types in the body, there are conflicting reports
100 on its expression levels and co-expression with ACE2 in different testicular cells (27, 28).
101 The presence of ACE2 receptor in multiple resident cells hypothetically makes the testes
102 a potential target for SARS-CoV-2 infection or endocytosis of VLPs. Alternatively,
103 systemic cytokine storm may induce bystander testicular inflammation, thus explaining
104 the orchitis symptom observed in COVID-19 patients. Therefore, the question remains
105 whether the gonadal injury is the direct or indirect consequence of virus infection in the
106 testes.

107

108 Here, using both 2D and 3D human multicellular testicular cell culture models, we show
109 that SARS-CoV-2 can enter testicular cells, but cannot establish productive virus
110 infection. Exposure of testicular cells with inflammatory media from SARS-CoV-2 infected
111 human airway epithelial cells led to apoptotic death of undifferentiated spermatogonia.
112 Further, only exposure to SARS-CoV-2 E protein but not S1 and N protein induced a pro-
113 inflammatory response that correlated with severe cytotoxicity. We also carefully
114 examined and validated the bystander effect of SARS-CoV-2 infection on testicular injury
115 using K18-hACE2 mice. Our data collectively provide the first evidence that the testicular

116 injury is not due to direct infection of SARS-CoV-2 but more likely an indirect effect of
117 exposure to systemic inflammation or SARS-CoV-2 antigens.

118

119 **Materials and Methods**

120 **Cells, Testicular Organoids, and Virus infection:**

121 Primary human SC and LC were obtained from iXCells Biotechnologies and ScienCell
122 Research Laboratories, respectively. Low passage SC and LC were cultured in DMEM/F-
123 12 and Leydig Cell Medium as described previously (29). The human testicular organoids
124 (HTO) consisting of primary SC, LC, peritubular myoid cells (PMC), and undifferentiated
125 spermatogonia (SSC) were generated from adult human testicular tissue procured
126 through the National Disease Research Interchange (NDRI) and cultured in ultralow-
127 attachment 96-well round-bottom plates as described by us previously (30, 31). For mixed
128 seminiferous tubule cells (STC) culture, seminiferous tubules from adult testes were
129 digested to isolate mixed cell populations of SC, PMC, and SSC as described previously
130 (32). SARS-CoV-2 USA-WA1/2020 strain was obtained from BEI Resources, propagated
131 once in Vero E6 cells, and used for all in vitro experiments. Cells cultured in 6-, 24-, or
132 96-well plates were infected with SARS-CoV-2 at MOI 1 or 10 and incubated for 1.5 hrs
133 at 37% and 5% CO₂. HTO were infected using 10⁴ PFU SARS-CoV-2. All SARS-CoV-2
134 manipulations were performed in the dedicated BSL3 facility at the John A. Burns School
135 of Medicine.

136

137 **Virus quantitation:**

138 SARS-CoV-2 titers in cell culture supernatants were measured by plaque assay using
139 Vero E6 cells and expressed as PFU per mL of supernatant (33). Intracellular viral
140 genome copies were measured in the RNA extracted from cell lysates and tissue
141 homogenates at different time points post-infection by qRT-PCR. Forward (nCoV_IP4-
142 14059Fw: GGTAAGTGGTATGATTTTC G) and reverse (nCoV_IP4-14146Rv:
143 CTGGTCAAGGTTAATATAGG) primers and probe (nCoV_IP4-14084Probe(+):
144 TCATACAAACCACGCCAGG [5']Fam [3']BHQ-1) were used specific for SARS-CoV-2
145 RNA-dependent RNA polymerase gene region and expressed as genome copies per μg
146 of RNA (34).

147

148 **Exposure of testicular cells to inflammatory media, COVID-19 plasma, and SARS-**
149 **CoV-2 proteins exposure:**

150 Human airway epithelial cells (HAE) grown on the inserts were infected with SARS-CoV-
151 2 at MOI 1 as described by others (35). Media was collected from the basal and the apical
152 side of inserts at different time points after infection. The basal side supernatant was
153 treated with ultraviolet light (UV) for 12 min to inactivate infectious virions. Different
154 testicular models were exposed to UV-inactivated HAE supernatant (1:1 ratio with cell
155 culture media). SC and STC cultures were also exposed to SARS-CoV-2 E, N or S1
156 proteins at 1 or 4 ng/ μL concentration. Plasma from 5 RT-PCR+ COVID-19 patients
157 collected during the symptomatic phase (days 4-6 of symptoms) under the UH IRB# 2020-
158 00367 and age-matched healthy controls were used in this study. STC and HTOs were
159 exposed to plasma (1:5 ratio with cell media) and cell viability and TUNEL staining assays
160 were conducted after 24 hrs of exposure. The E protein was also incubated with 1X

161 proteinase K for 3 hrs before exposing to SC. In some experiments, E and S1 exposure
162 were conducted in the presence or absence of neutralizing antibodies against toll-like
163 receptor 2 and 4 (TLR2 and TLR4) antibodies (ThermoFisher Scientific Cat. # MA5-
164 16200 and Cat # MA180122 at 1:250 and 1:500 concentration respectively).

165

166 **RT-PCR analysis:**

167 Total RNA was extracted from mock- and SARS-CoV-2-infected SC, LC, STC, and HTO
168 lysates using RNeasy mini kit (Qiagen) and synthesized into cDNA, and change in mRNA
169 transcripts of inflammatory genes was measured by qPCR, as described previously (36).
170 Specific primer sequences are either previously described (29, 37) or shown in Table 1.
171 The housekeeping gene *GAPDH* was used to normalize fold change values of antiviral
172 genes, with respective controls used as a reference control.

173

174 **Cell Viability:**

175 Cell viability of different 2D cultures at different time points of infection or exposure to
176 virus proteins or HAE supernatant was determined using the CellTiter 96 AQueous One
177 Solution cell proliferation assay (G3582; Promega), while HTO viability was determined
178 by the CellTiter-Glo 3D cell viability assay (Promega G9681; Promega) as described
179 previously (29).

180

181 **Enzyme-Linked Immunosorbent Assays:**

182 All commercially available ELISA kits were purchased from Invitrogen Thermo Fisher
183 Scientific and the assays were performed according to the manufacturer's instructions.

184 The kits used were IL-6 Human Instant ELISA Kit (Cat. # BMS213INST), IL-1 β Human
185 Instant ELISA Kit (Cat. # BMS224INST), and TNF-alpha human Instant ELISA Kit (Cat. #
186 BMS223INST). All samples including HAE supernatant at different time points and
187 plasma from COVID-19 patients were run in triplicate and levels were expressed as
188 pg/mL media or plasma.

189

190 **Immunofluorescence and TUNEL assay:**

191 Mock and infected LC, SC, or STC grown on glass coverslips were fixed with 4% PFA,
192 permeabilized with 0.1% Triton X-100 in PBS, and blocked with 5% bovine serum albumin
193 in PBS. Cells were then incubated with primary antibodies against anti-Spike (GeneTex,
194 GTX632604 at 1:500 dilution), followed by fluorophore-conjugated secondary antibody
195 (Invitrogen Alexa Fluor 488-conjugated sheep anti-rabbit, 1:5000 dilution), and examined
196 using an AxioCam MR camera mounted on a Zeiss Axiovert 200 microscope. TUNEL
197 assay was performed using the Promega DeadEnd™ Fluorometric TUNEL System
198 according to the manufacturer's instructions. Undifferentiated spermatogonia were also
199 stained for the well-established cell-specific marker, ubiquitin carboxyl-terminal esterase
200 L1 (UCHL1) (29) using rabbit anti-human UCHL1 (Sigma, HPA005993 at 1:1,000
201 dilution). The secondary antibody was Alexa Fluor 594-conjugated goat anti-rabbit
202 (Invitrogen; 1:5000 dilution).

203

204 **Infection of *K18-hACE2* mice**

205 *B6.Cg-Tg(K18-ACE2)2Prlmn/J* (*K18-hACE2*) mice (#034860) were obtained from the
206 Jackson Laboratory. All mouse experiments were performed according to the animal

207 experimental guidelines issued and approved by Institutional Animal Care and Use
208 Committee of the University of Hawaii at Manoa. All mouse infection experiments were
209 conducted using SARS-CoV-2 USA-HI-B.1.429 isolated from a local COVID-19 patient in
210 2020 that is very similar to the SARS-CoV-2 CoV/USA-WA1/2020 (38) at the dedicated
211 ABSL2/3 facility at the UH. Eight to twelve weeks old *K18-hACE2* mice were inoculated
212 with 2×10^4 PFU SARS-CoV-2 via the intranasal route and observed daily to record body
213 weights and clinical symptoms and were sacrificed when weight loss greater or equal to
214 20% was observed. The lung, heart, and testis tissues were harvested in a separate set
215 of experiments at 3, 5, and 8 days post infection (dpi) and were either flash-frozen or fixed
216 in 4% PFA to determine virus genome copies and histopathological changes respectively.
217 RNA was extracted from frozen tissues as described previously (39) and virus RNA and
218 expression of different host genes were measured by RT-PCR. Testes were also fixed in
219 Bouin overnight, and then stored in 70% ethanol prior to embedding in paraffin wax,
220 sectioning at 5 μ m, and staining with Periodic acid Schiff and hematoxylin (PASH) to
221 identify histopathological changes.

222

223 **Statistical Analysis:**

224 All data were analyzed with GraphPad Prism 9.3.1 software. Statistically significant
225 differences between different groups were determined using unpaired t-tests. SARS-
226 CoV-2 titers and viability data are reported as means \pm standard error of the mean
227 (SEM) from at least three or more independent experiments. Gene expression (mRNA
228 fold change) and ELISA data are reported as means \pm standard errors of the means

229 (SEM) from ≥ 3 independent experiments. A *p*-value of <0.05 was considered statistically
230 significant for all analyses.

231

232 **Results:**

233 **Human testicular cells do not support productive SARS-CoV-2 infection.** We, and
234 others, have previously shown that human testicular cells like LC and SC express ACE2
235 (40). Therefore, we first determined the infection kinetics of SARS-CoV-2 in different
236 testicular cell models including primary human SC and LC, 2D culture of mixed STC and
237 3D HTOs. Low levels of viral RNA in the range of log 2-3 genome copies were detected
238 in all cell models, but the virus copies did not increase between 24 and 96 hrs post-
239 infection (hpi, Fig. 1A). Virus titers measured in the supernatant by plaque assay did not
240 show the presence of infectious virions in any cell types at any time point (Fig. 1B). These
241 data suggest that productive replication of SARS-CoV-2 did not occur in these human
242 testicular cell models. Infection of SC and LC at higher MOI 10 also did not show any
243 SARS-CoV-2 released in the supernatant over 96 hours (Fig. S1A-B). In addition, we
244 were not able to detect the SARS-CoV-2 spike protein using immunofluorescence assay
245 in infected SC and LC (Fig. 1C), further demonstrating the lack of SARS-CoV-2 replication
246 in these primary cell cultures.

247

248 Since exogenous serine proteases have been shown to facilitate SARS-CoV-2 entry and
249 replication in other low TRMPSS2 expressing cells (41), we next assessed if TRMPSS2
250 is expressed in LC and SC and if the presence of exogenous serine protease activity
251 would make testicular cells susceptible to infection. We observed that there was minimal

252 to no TMPRSS2 staining in these cells (Fig. S1C). Assuming that this could be a factor
253 explaining non-productive SARS-CoV-2 infection in these cell types, we analyzed virus
254 replication in the presence of exogenous serine protease. SARS-CoV-2 infection of SC
255 pre-incubated with 5 µg/mL trypsin, a serine protease, which at this concentration does
256 not interfere with cell attachment and has been used by others to enhance SARS-CoV-2
257 entry in other cell types (42), also did not result in increased intracellular virus RNA (data
258 not shown) or infectious virions in the supernatant (Fig. 1D). To further evaluate if SARS-
259 CoV-2 entry alone can activate an inflammatory response, we measured the mRNA levels
260 of key cytokines associated with COVID-19 in SC, LC, and HTO at 48 hpi. Consistently,
261 gene expression of inflammatory cytokines including *IL6*, *TNFA*, and interferon beta 1
262 (*IFNB1*) was not altered in any of these testicular cell types (Fig. 1E). Collectively, our
263 data strongly suggest that even though SARS-CoV-2 RNA is detected in testicular tissue
264 from COVID-19 patients, it does not establish a productive infection in resident human
265 testicular cells.

266

267 **SARS-CoV-2 infection of human airway epithelial cells is associated with loss of**
268 **air-liquid barrier integrity and production of inflammatory cytokines.**

269 Several clinical studies have linked SARS-CoV-2-associated cytokine storm with injury to
270 the kidney, heart, and brain (43–49). Therefore, we next tested if the testicular damage
271 was an indirect effect of the inflammatory mediators derived from SARS-CoV-2 infection
272 of other cell types. To begin the evaluation of the bystander effect, we first infected well
273 differentiated 2D cultures of human airway epithelial cells (HAE) grown on transwell
274 inserts at MOI 1 and measured infectious virions released both on the apical and basal

275 sides of the inserts. The plaque assay demonstrated a significant increase in the virus
276 titers at 2 days post-infection (dpi) that peaked at day 3 and subsequently declined by >2
277 logs by 8 dpi (Fig. 2A). A similar trend was observed in intracellular virus genome copies,
278 with peak virus replication at 4 dpi (Fig. 2B). Further, SARS-CoV-2 infection also
279 compromised the integrity of the air-liquid barrier (Fig. 2C). The transepithelial electrical
280 resistance (TEER) readings showed a decline starting at 3 dpi with significantly lower
281 values at 5 and 6 dpi, suggesting a loss in the barrier integrity most likely a result of virus-
282 induced CPE. Peak virus titers also correlated with significant induction of key
283 inflammatory cytokine genes like *TNFA* and *IL6*, and antiviral genes including interferon-
284 induced protein with tetratricopeptide repeats one (*IFIT1*) at 4 dpi (Fig. 2D).

285

286 The production of key cytokines in the HAE supernatant was further confirmed and
287 compared to plasma from COVID-19 patients during the acute stage of the disease (4-6
288 days of symptom onset) using ELISA. While there was no difference in the levels of IL-
289 1 β , TNF- α , and IL-6 in mock and infected HAE supernatant at 1 dpi (data not shown), as
290 seen in Fig. 3A-C, their levels were significantly higher in the infected supernatant at 4
291 dpi that correlated with peak virus titers. Further, interestingly, the levels of these
292 cytokines were comparable to the levels seen in the plasma of COVID-19 patients (Fig.
293 3A-C). Collectively, this data shows that supernatant from SARS-CoV-2 infected HAE
294 mimics the profile of select cytokines observed in COVID-19 patients and can be used to
295 evaluate the indirect effect of infection on 2D and 3D human testicular models.

296

297 **SARS-CoV-2 infection-derived inflammatory mediators cause indirect cytotoxicity**
298 **on primary human testicular cells**

299 To determine the cytotoxic effects of SARS-CoV-2 infection-derived inflammatory
300 mediators on testicular cells, we exposed STC to UV-inactivated supernatant from HAE
301 and COVID-19 plasma and measured the cell viability. As seen in Fig. 3D, at 24hrs post-
302 exposure, the cell viability of the STC exposed to infected HAE supernatant declined by
303 approximately 30%. In contrast, the viability of cells exposed to supernatant from mock-
304 infected HAE cells was comparable to untreated cells. Similarly, an almost 50% decrease
305 in the viability of STC and HTO was observed when exposed to COVID-19 plasma as
306 compared to healthy control plasma (Fig. 3E). To further understand if cell death following
307 exposure to inflammatory plasma also triggers cytotoxic cytokines, we measured mRNA
308 levels of *IL6*, *IL1B*, and *TNFA* genes. There was a significant increase in the transcripts
309 of these cytokines as well as Bcl-2 associated protein X (*BAX*), a pro-apoptotic gene, in
310 HTO exposed to COVID-19 plasma (Fig. 3G). Interestingly, SC alone exposed to infected
311 HAE supernatant did not exhibit any significant change in cell viability at 24 hours post-
312 exposure (Fig. 3F). We also did not observe a similar induction of cytokines and *BAX* in
313 SC following exposure to HAE supernatant (Fig. 3H), suggesting that the cell death seen
314 in our mixed 2D and 3D cultures was most likely of the delicate germ cells.

315

316 To further validate that undifferentiated spermatogonia are more susceptible to cell death,
317 we conducted a TUNEL assay on STC exposed to both UV-inactivated HAE supernatant
318 and COVID-19 plasma for 24 hours. As seen in Fig. 4A, very few TUNEL-positive cells
319 were detected in STC that were untreated or treated with mock HAE supernatant.

320 However, TUNEL positive cells increased significantly from 2% in mock to 10% in STC
321 treated with infected supernatant for 24 hrs (Fig. 4B). Similarly, TUNEL positive cells
322 increased from 6% in healthy control plasma-treated cells to 20% in COVID-19 plasma-
323 treated STC (Fig. 4A-B). The cells were also co-stained for UCHL1, a well-established
324 undifferentiated spermatogonia marker, and merged pictures in Fig. 4C show that UCHL1
325 positive cells were also TUNEL positive (yellow) in STC exposed to infected supernatant
326 from HAE cells. However, in STC exposed to COVID-19 plasma, we observed apoptotic
327 cell death in both UCHL1 positive and UCHL1 negative cells (white arrows). These
328 findings suggest that mediators derived from SARS-CoV-2 infection in the HAE
329 supernatant and COVID-19 plasma can cause an inflammatory response in testicular
330 cells and apoptotic cell death.

331

332 **SARS-CoV-2 envelope protein causes severe damage in testicular cells**

333 Virus-induced bystander cell death can be because of both, the inflammatory cytokines
334 or viral proteins secreted by infected cells in the bloodstream, as shown in other viruses
335 like Dengue and Ebola (50–52). As a result, we investigated whether SARS-CoV-2 S1,
336 N, and E proteins can cause cytopathic effects in various testicular cells. The SC were
337 exposed to recombinant SARS-CoV-2 E, N, and S1 at different concentrations (0.25, 0.5,
338 1 and 4ng/ μ L) and cell viability was quantified at 24hrs post-exposure. While the S1 and
339 N proteins did not affect the cell viability, we observed a significant reduction in the viability
340 after exposure to the E protein in a dose-dependent manner with the most severe cell
341 death seen in cells treated with 4 ng of E (Fig. 5A). Further, to examine whether SC
342 cytotoxicity was specific to envelope protein, we pre-incubated envelope protein with

343 proteinase K. SC death was reversed when E protein was inactivated with proteinase K
344 indicating that E alone can cause SC death (Fig. 5A). We then treated STC with E and
345 S1 at concentrations 1 and 4 ng/well and measured cell death at 4 and 24hrs post-
346 exposure and demonstrated a 30-40% decrease in cell viability only in E-treated STCs
347 (Fig. 5B). Similarly, E protein treated HTO showed a 40% reduction in cell viability at
348 24hrs post-exposure (Fig. 5C). To further validate if the cell death associated with the E
349 protein is associated with cytokine induction, we measured the levels of cytotoxic
350 cytokines like IL-6, TNF- α , and IL-1 β in the supernatant of STC exposed to E and S1
351 proteins using ELISA. As seen in Fig. 5D-F, these cytokines were either absent or
352 detected at very low levels in mock and S1-treated STC. However, their levels were
353 significantly increased by E protein as early as 4hrs post-exposure and further increased
354 at 24hrs post-exposure. The induction of IL-6, TNF- α , and IL-1 β was also validated at the
355 transcript level (Fig. 5G), and the fold-increase of these cytokines at 24 hrs post-exposure
356 to E protein correlated well with the ELISA data. Moreover, we also observed a > 20-fold
357 increase in the transcripts of the pro-apoptotic gene BAX (Fig. 5G).

358

359 Secretory virus proteins can activate inflammatory pathways following binding to cell
360 surface receptors including TLR2 and/or 4 (50, 53). Therefore, to examine the
361 involvement of TLR2 and 4 in the cytopathic effects associated with E, we exposed STC
362 to E protein in the presence or absence of neutralizing antibodies against TLR2 and TLR4.
363 As seen in Fig. 5H, while the presence of neutralizing TLR4 antibody did not affect the
364 cell viability outcome, there was a nearly complete reversal in the cell death caused by E
365 protein in the presence of anti-TLR2. Similarly, there was a reversal in the cell death

366 induced by E protein in SC in the presence of anti-TLR2 (data not shown) suggesting that
367 the downstream response of the E protein involves activation of the TLR2 receptor
368 signaling.

369

370 To further determine if the cellular uptake of E protein is required for the cytopathic effects,
371 we visualized STC exposed to E and S1 proteins conjugated with fluorophore AF488
372 using confocal microscopy. As seen in Fig. 6A-B, E protein was internalized efficiently by
373 STC after 12hrs of exposure and was detected mainly in the cytoplasm of these cells
374 (white arrows). The intensity of the staining for Phalloidin, a marker for actin filaments,
375 was significantly reduced in E protein-treated STC (Fig. 6C-D) indicating that the
376 cytoskeleton was degraded. Further, the DNA (blue arrows) was ejected from the nuclei
377 of E protein-positive cells (Fig. 6A), suggesting significant disruption of STC homeostasis.
378 In contrast, it appeared that the internalization of S1 protein was significantly lower than
379 E protein and did not lead to disruption of the cytoskeleton or overall morphology (Fig.
380 6C-D). Collectively, these data firmly establish that the SARS-CoV-2 E protein can be
381 efficiently internalized by testicular cells and causes severe cell death that is dependent
382 on TLR2 and is accompanied by an increase in the production of inflammatory cytokines.

383

384 **SARS CoV-2 infection of K18-hACE2 mice leads to testicular inflammation and**
385 **injury.**

386 To characterize the effect of SARS-CoV-2 infection on the testis in vivo, we utilized the
387 transgenic K18-hACE2 mouse model that expresses high levels of human ACE2 in the
388 lung, low levels in the brain, and none in other epithelial cells like GI and liver (54).

389 Compared to other animal models like hamsters, ferrets, and primates, the K18-hACE2
390 mouse model best mimics different aspects of COVID-19 including severe disease,
391 systemic cytokine storm, and tissue injury (55–57). Since testicular injury is most
392 commonly seen in moderate to severe COVID-19 patients, these mice are best suited for
393 studying the indirect effects of SARS-CoV-2 infection on the testis. Intranasal inoculation
394 of K18-hACE2 mice with 2×10^4 PFU of SARS-CoV-2 led to almost 70-80% mortality (Fig.
395 7A) that replicated outcomes of similar studies (58, 59). Virus genome copies in the lungs
396 peaked at 3 dpi and remained high at 5 dpi (Fig. 7B) and were almost cleared by 8 dpi.
397 However, virus mRNA was either found at very low levels in the heart in 50% of mice (Fig.
398 7B) or not detected at all in other peripheral tissues like the kidney and spleen (data not
399 shown). Interestingly, we also did not detect virus RNA in any of the testes at any time
400 point (Fig. 7B). Further, plaque assay of the tissue lysates demonstrated high virus titers
401 present only in the lung lysates at 3 and 5 dpi but not in heart and testis lysates (**Fig. 7C**).
402 We next assessed if inflammation markers are induced by the virus in the testes
403 independent of active virus replication. As expected *IL6* and *TNFA* were upregulated in
404 the lungs and correlated with viral titers. Interestingly, despite no viral RNA, we found that
405 the transcripts of these inflammatory cytokines were significantly increased in the testes
406 at 5 and 8 dpi.

407

408 To further assess if there is an indirect effect of SARS-CoV-2 infection on the testes, we
409 conducted a histopathological assessment of PAS-H-stained sections of the testes. The
410 uninfected control males had normal testis and tubular organization (Fig. 7E, i-ii).
411 Seminiferous tubules were well-developed and tightly packed, with limited interstitial

412 space. Tubular basal and adluminal compartments were tightly connected, and germ cells
413 were properly organized, with spermatogonia, spermatocytes, and round spermatids
414 visible at successively higher levels within the epithelium. Leydig cells in the interstitium
415 and Sertoli cells and germ cells within tubules were normal and healthy. However, after
416 SARS-CoV-2 infection, various testicular abnormalities were noted in both the interstitium
417 and seminiferous tubules at 5 and 8 dpi. Interstitial edema of varying severity levels was
418 observed in some areas, either as increased interstitial space between adjacent
419 seminiferous tubules (Fig. 7E, iii at 5 dpi) or with red-stained fluid filling the interstitial
420 space (Fig. 7E, v at 5 dpi). Leydig and Sertoli cells, as well as most germ cells, appeared
421 healthy. However, in some areas within seminiferous tubules, germ cells were severely
422 disorganized, in extreme cases, randomly occupied space throughout the tubule (Fig. 7E,
423 iii, d5). In some areas, the tubules were found to be congested with evidence of
424 prematurely sloughed germ cells in the lumen (Fig. 7E, v at 5 dpi). These results validate
425 our in vitro data and collectively demonstrate that despite no active replication, SARS-
426 CoV-2 infection results in interstitial and tubular abnormalities in the testis of hACE2 mice.
427 These injury markers are similar to what has been observed in humans (7, 60, 61)
428 suggesting that these mice can be used as a model to systematically delineate the indirect
429 effect of SARS-CoV-2 on different aspects of male reproductive health.

430

431 **Discussion:**

432 Emerging clinical studies highlight that SARS-CoV-2 infection-associated testicular pain,
433 reduced testosterone levels and altered sperm counts are more common in COVID-19
434 patients than previously thought (5, 7, 8). Further, postmortem studies have

435 characterized several features of testicular injury including the detachment of SC,
436 apoptosis of undifferentiated spermatogonia, and infiltration of leukocytes in the
437 interstitium. However, the association of these injury markers with virus infection
438 kinetics is not clear. Here, we used different 2D and 3D culture models of primary
439 human testicular cells to show that (i) While SARS-CoV-2 can enter LC and different
440 seminiferous tubular cells, it cannot establish a productive infection in any of these cell
441 types (ii) Inflammatory media from infected airway epithelial cells and plasma from
442 COVID-19 can trigger inflammatory cytokines production and cytotoxicity in testicular
443 cells (iii) Exposure of testicular cells to SARS-CoV-2 E protein increases expression of
444 inflammatory cytokines and induce severe cytotoxicity that is dependent on TLR2 and
445 (iv) intranasal inoculation of K18-hACE2 mice depicted leads to testicular damage in the
446 absence of any replicating virus, thus overall supporting the fact that testicular damage
447 is a bystander effect of SARS-CoV-2 infection.

448

449 Susceptibility to SARS-CoV-2 infection is highly cell type-specific and dependent on the
450 presence of entry receptors like ACE2 and serine protease, TMPRSS2 (41). While
451 robust infection of lung alveolar type II epithelial cells is linked to high ACE2 expression,
452 the absence of this receptor and serine proteases is the main reason for the human
453 macrophages, natural killer (NK) cells, dendritic cells, and vascular endothelial cells not
454 being susceptible to SARS-CoV-2 (26, 62). Enterocytes in the gastrointestinal (GI) tract
455 that express very high levels of ACE2 and TMPRSS2 are susceptible to SARS-CoV-2,
456 but the virions produced are very low compared to alveolar type II cells (63, 64)
457 suggesting that just the presence of receptors alone is not enough to establish

458 productive viral infection. Although several groups, including ours, have reported high
459 levels of ACE2 and TMPRSS2 in the human testes including LC, SC, and
460 undifferentiated spermatogonia (26, 28), direct evidence of infection of human testicular
461 cells is lacking. The presence of SARS-CoV-2 RNA in the human postmortem testes
462 tissue is not a common observation and is limited to RT-PCR detection of very low
463 levels of viral genome copies (7). Even in the animal models, subgenomic SARS-CoV-
464 2 RNA was detected only in the intratesticular inoculated hamsters (65). Further, the
465 suggestion that SARS-CoV-2 can infect testes of the rhesus macaques by Madden and
466 colleagues was based on the staining of Spike protein (66) and does not confirm if testis
467 can support active replication of the virus. Therefore, taken together, our data showing
468 the total absence of SARS-CoV-2 virions in the media and no cell death in infected
469 cells, provide direct evidence that SARS-CoV-2 cannot establish productive replication
470 in different testicular cells in vitro. Since virus replication is directly associated with
471 robust inflammatory response, the absence of the induction of the key cytokines in
472 infected cells again supports our notion that none of our in vitro testicular cell models
473 supported virus replication. We speculate this can be either due to the absence of co-
474 localization of TMPRSS2 and ACE2 in the same cell type or the lack of specific host
475 components required for virus replication.

476

477 However, robust data now exists suggesting that COVID-19 leads to severe testicular
478 injury and affects testis function (7). In the absence of active virus replication, tissue
479 injury can be mediated by cytokines storm or exposure to virus proteins (67–69). Mild
480 and severe COVID-19 patients exhibit systemic cytokine profiles similar to other

481 infectious diseases such as Ebola virus disease (EVD) (70). The elevated levels of
482 $TNF\alpha$, IL6, IL1, $IFN\gamma$, and monocyte chemoattractant protein 1 (MCP1) reported in
483 severe EVD are associated with severe damage to the kidney and vascular system
484 (71). Similarly, dengue nonstructural protein (NS1) shed during acute infection acts as a
485 viral pathogen-associated molecular pattern that activates TLR4 on leukocytes and
486 endothelial cells leading to inflammation and endothelial dysfunction (52). Therefore, we
487 next focused on addressing our alternative hypothesis that testicular injury results from
488 the bystander effect of systemic cytokines. The key cytokines induced by SARS-CoV-2
489 infected HAE cells support findings from previous studies (72, 73). Our observation of
490 the comparable levels of cytokines in HAE media and COVID-19 plasma is encouraging
491 and supports the notion that inflammatory HAE supernatant can be used to study
492 bystander effects of SARS-CoV-2 associated cytokine storm. Transmigration of SARS-
493 CoV-2 from the apical to the basal side of the inserts has been reported previously, but
494 our data is the first to correlate virus replication with the induction of key inflammatory
495 cytokines in the supernatant of this 2D model. Interestingly, both STC and HTOs
496 exhibited significantly higher cytotoxicity post-exposure to inflammatory media from
497 infected HAE and plasma from COVID-19 patients compared to SC (Fig. 3). Our
498 speculation that this difference is most likely because of the presence of delicate
499 undifferentiated spermatogonia in the STC and HTO was confirmed by the TUNEL
500 assay and agrees with germ cell depletion seen in the testis from COVID-19 patients
501 (6).

502

503 While the secretion of E protein by infected cells in COVID-19 patients is not yet
504 determined, two recent studies have shown the presence of SARS-CoV-2 S1 and N
505 proteins in the plasma of 64% of COVID-19 patients in the range of 5-10,000 pg/mL
506 plasma (74). Other studies also report the presence of S1 in the urine and saliva of
507 COVID-19 patients (75) suggesting that the shedding of different SARS-CoV-2 proteins
508 is an outcome of infection and might be an event associated with severe disease.
509 Additionally, the presence of VLPs in different tissues including the testes and the brain
510 is also commonly reported (16, 17). Both S1 and N proteins have been shown to induce
511 inflammation and cell death in macrophages (20, 21), suggesting the potential of these
512 proteins to independently cause cytopathic effects. On the other hand, Zheng and
513 colleagues reported that exposure to S1 did not induce any inflammatory response
514 compared to E in bone marrow-derived macrophages (BMDMs) (76). Therefore, although
515 it was surprising that S1 did not induce any cytopathy in SC and STC, we believe this
516 might be because S1 was not efficiently internalized in these cells (Fig. 6) compared to
517 more phagocytic macrophages. Our data, however, agrees with previous in vitro and in
518 vivo studies that also showed induction of cytokine response, cell death, and lung
519 pathology by SARS-CoV-2 E protein and dependence on the TLR2 pathway (76, 77).
520 There is a consensus view that E, a glycosylated transmembrane protein with ion channel
521 activity, plays an important role not only in viral replication and virion assembly but also
522 in pathogenicity including induction of cytokines and cell death (69). These studies and
523 our data collectively suggest that E protein can trigger an inflammatory response and
524 cause cytopathic effects in the testicular cells independent of SARS-CoV-2 replication.
525

526 An important highlight of our study is the validation of the in vitro data in the K18-hACE2
527 mouse model. Since high expression of hACE2 is mainly in the lungs, as expected very
528 high viral replication was detected in this organ leading to high mouse mortality. Elevated
529 levels of inflammatory cytokines have been reported before not only in the lungs but also
530 in the plasma of these mice (78). Therefore, we believe that the K18-hACE2 mouse model
531 is an appropriate model for studying the bystander effect of SARS-CoV-2 infection. Our
532 data provide the first evidence that the testicular pathological events similar to what is
533 reported in postmortem testis tissue from COVID-19 patients (7) manifest in the K18
534 hACE2 mice. Seminiferous tubule disorganization, germ cell sloughing, and germ cell
535 apoptosis that we observed in mouse testis sections are well-characterized hallmarks of
536 testicular injury thus establishing K18-hACE2 mice as a tool that would allow to
537 systematically delineate underlying mechanisms at the molecular level in future studies.

538

539 Although gross alterations in male reproductive health including lower testosterone levels
540 and decreased sperm count have been well established, our understanding of the
541 mechanisms of SARS-CoV-2 infection-associated testis injury is limited. Few studies
542 have reported presence of viral antigens and/or VLPs in the testis by immunostaining,
543 based on which it has been proposed that testicular injury is the result of direct SARS-
544 CoV-2 infection (79, 80). However, our data present direct evidence that despite the
545 expression of ACE2, human testicular cells do not support productive infection of SARS-
546 CoV-2. Our study also greatly improves our understanding of the indirect effect of virus
547 infection on testicular injury. Collective data suggest that during peak infection, exposure
548 of testicular cells to both cytokine storm and viral antigens may trigger pathological

549 pathways and apoptotic death of germ cells that may be responsible for orchitis symptoms
550 and lower sperm counts reported in COVID-19 patients. However, further investigations
551 are warranted to characterize the testicular injury's short- and long-term effects on fertility
552 markers like testosterone levels, and the specific pathways associated with pathological
553 events. Finally, our findings presented herein suggest the need for long-term follow-up of
554 male reproductive health markers in moderate to severe male COVID-19 patients
555 following recovery.

556

557 **Acknowledgements**

558 This work was partially supported by grants R21AI129465 (SV), R21AI140248 (SV),
559 Victoria S. And Bradley L. Geist Foundation (MDT and SV), George F. Straub Trust &
560 Robert C. Perry Fund (MDT and SV), and NIH HD072380 and HD106936 (MAW). We
561 thank Ms. Mallory Wilson for technical help with tissue culture and RT-PCR experiments.

562

563 **Figure legends**

564 **Figure 1. Lack of SARS-CoV-2 does not establish a productive infection in human**

565 **testicular cells. (A)** Primary SC, LC, STC and HTO were infected with SARS-CoV-2 at

566 MOI 1 and intracellular virus levels were determined at 24, 48 and 96 hrs post-infection

567 (hpi) using qRT-PCR. **(B)** SARS-CoV-2 titers in the supernatant from infected Vero E6,

568 SC, LC, STC and HTO at MOI 1 were measured using plaque assay. **(C)**

569 Representative images of SARS-CoV-2 (MOI 1) infected SC, LC and Vero E6 cells

570 stained for SARS-CoV-2 using anti-Spike (green) at 48 hpi. **(D)** SARS-CoV-2 progeny

571 titers measured by plaque assay in the supernatant from infected SC and LC pre-

572 incubated with 5µg/mL of exogenous serine protease. **(E)** The mRNA fold change of
573 *TNFA*, *IL6*, and *IFNB1* measured in infected SC, LC, and HTO (MOI 1) using qRT-PCR
574 at 48 hpi. The error bars represent the \pm SEM of at least 4 independent infections.

575

576 **Figure 2. Human airway epithelial cells are highly permissive to SARS-CoV-2**
577 **infection and produce inflammatory cytokines. (A)** Fully differentiated primary HAE
578 grown on inserts were infected with SARS-CoV-2 (MOI 1) and infectious virions
579 released on the apical and basal side were quantified using plaque assay **(B)** SARS-
580 CoV-2 RNA measured in HAE at days (D) 1, 2, 4 and 8 post-infection using qRT-PCR
581 **(C)** The transepithelial electrical resistance (TEER) was used to measure the integrity of
582 the air-liquid barrier of HAE inserts at different days post-infection (MOI 1), and
583 expressed in Ohm*cm² (Ω cm²). **(D)** The mRNA fold-change of *TNFA*, *IL6*, *IFIT1* and
584 *IFNB1* genes was measured in infected HAE at MOI 1 using qRT-PCR. Error bars
585 represent \pm SEM of at least 3 independent infections. **p<0.01; ****p<0.0001.

586

587 **Figure 3. Bystander effect of SARS-CoV-2 on different testicular cells. (A-C)** IL6,
588 IL1 β and TNF α levels were measured by ELISA in the mock and UV-inactivated
589 supernatant from infected HAE cells (Inf) (4 dpi), and control (healthy donor) and
590 COVID-19 plasma. **(D)** Percent cell viability assessed in STC at 24 hrs following
591 exposure to UV-inactivated HAE infected (Inf Sup) or control supernatant (Mock Sup),
592 **(E)** Percent viability of STC and HTO exposed to control (Cont) or COVID-19 plasma for
593 24 hrs post-exposure calculated by comparing to corresponding untreated cells **(F)**
594 Viability of SC exposed to UV inactivated HAE infected (Inf Sup) or control (Mock Sup)

595 supernatant at 24hrs post-exposure. **(G)** The fold-change of *IL6*, *IL1B*, *TNFA*, and *BAX*
596 transcripts in HTO exposed to control and COVID-19 plasma was measured using qRT-
597 PCR (error bar represents \pm SEM of 4 data points and each data point is a pool of RNA
598 from 10 HTO). **(H)** The effect of exposure of HAE supernatant on the mRNA expression
599 of *IL6*, *IL1B*, *TNFA* and *BAX* in SC was determined by RT-PCR. Error bars represent
600 \pm SEM of at least 3 independent exposures. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$;
601 **** $p < 0.0001$

602

603 **Figure 4. SARS-CoV-2 infection-derived factors promote apoptotic cell death of**
604 **undifferentiated spermatogonia. (A)** Representative TUNEL staining in STC exposed
605 to supernatant from mock (HAE Sup-Mock) and infected HAE cells (HAE Sup-Inf), and
606 to control and COVID-19 plasma for 24 hrs. The green fluorescence depicts TUNEL+
607 cells. **(B)** Quantification of percent TUNEL positive cells and mean fluorescence
608 intensity in each group. Data represents the average of at least six fields per coverslip
609 from 3 independent experiments captured using Image J. Error bars represent \pm SEM.
610 **(C)** STC exposed to UV-inactivated HAE supernatant and COVID-19 plasma were co-
611 stained with TUNEL and UCHL1, a marker for undifferentiated spermatogonia including
612 spermatogonia stem cells (SSC). Co-localization was evaluated by merging TUNEL and
613 UCHL1 and white arrows indicate overlapping green and red staining (yellow).

614 *** $p < 0.001$; **** $p < 0.0001$

615

616 **Figure 5. SARS-CoV-2 Envelope protein triggers cell death and inflammation via**
617 **TLR2. (A)** SC cell viability was assessed 24 hrs after exposure to recombinant SARS-

618 CoV-2 spike subunit 1 (S1), nucleocapsid (N) and envelope (E) proteins at 0.25, 0.5, 1
619 and 4ng/ μ L media in 96-well plates. Exposure of E protein was also conducted in the
620 presence of proteinase K enzyme **(B)** STC were exposed to S1 and E protein at 1 and
621 4ng/ μ L media and the percent change in cell viability was calculated after 24 hrs. **(C)**
622 Percent change in the cell viability of HTO was evaluated 24 hrs after exposure to
623 recombinant SARS-CoV-2 E and S1 at 4ng. **(D-F)** TNF α , IL6 and IL1 β levels in the
624 supernatant STC were measured using ELISA after exposure to recombinant E and S1
625 proteins. **(G)** mRNA fold change of *IL6*, *IL1B*, *TNFA* and *BAX* in STC exposed to 4ng/ μ L
626 of E and S1 proteins was measured at 24 hrs post-exposure using qRT-PCR. **(H)** SC
627 were treated with E protein (4ng) in the presence or absence of TLR2 and TLR4
628 neutralizing antibodies and percent cell viability was measured after 24 hrs of exposure.
629 Error bars represent an average of at least 3-5 independent exposures (\pm SEM).
630 **p<0.01; ***p<0.001; ****p<0.0001.

631
632 **Figure 6. The uptake of SARS-CoV-2 envelope protein disrupts the morphology of**
633 **the seminiferous tubule cells.** STC were exposed to green fluorophore-conjugated E
634 and S1 proteins (4ng) and the uptake was evaluated after 24 hrs by detecting
635 intracellular virus antigens (green) following staining with DAPI and Phalloidin (red), a
636 marker for actin filaments. **(A)** Representative confocal microscopy image show E
637 protein localization in the cytoplasm (white arrows) and dramatic loss of actin filaments.
638 High-power magnification pictures depict dramatic disruption of the nuclear
639 compartment with genetic material being ejected from the nucleus (blue arrows). **(B)**
640 The mean fluorescence intensity (MFI) of intracellular E and S1 proteins, and **(C)** actin

641 filament length and **(D)** MFI were assessed using Image J in 3 different fields from at
642 least 2 independent experiments. * $p < 0.05$; ** $p < 0.01$; **** $p < 0.0001$.

643

644 **Figure 7. SARS-CoV-2 infection in K18-hACE2 mice exhibits severe testicular**
645 **pathology. (A)** Eight to twelve weeks old male and female K18-hACE2-transgenic mice
646 were inoculated via the intranasal route with 10⁴ PFU SARS-CoV-2. Survival was
647 monitored for 14 days (n=15). **(B)** Viral RNA in the lung, heart, and testis at days 3, 5,
648 and 8 post-infection (dpi) measured by RT-qPCR. The dotted horizontal line indicates
649 the limit of detection. **(C)** Plaque assay was used to determine SARS-CoV-2 titers in the
650 lung, heart, and testis tissue homogenates. **(D)** Fold change in the gene expression of
651 inflammatory genes *IL6* and *TNFA* was determined in the lung and testis homogenates
652 using qRT-PCR (two independent experiments; n = 4-6 males per time point). **(E)** PAS-
653 staining of testis sections from K18-hACE2 mice following mock (i-ii) or SARS-CoV-2
654 infection at 5 (iii, v) and 8 (iv) dpi. Images show seminiferous tubules from control mice
655 with normal tubular morphology and healthy Leydig (black arrows) and Sertoli cells
656 (white arrows). Insets show healthy round and elongated spermatids typical of the
657 stage. In sections from SARS-CoV-2 infected mice noted abnormalities were interstitial
658 edema (IE) (iii and vi), lack of lumen and overall cell disorganization (iii), separation of
659 germ cell layers from the basal membrane (iv), sloughing of healthy and apoptotic germ
660 cells into the lumen (v, arrowhead and inset). Insets, 3x magnification. Scale, 100 μ m.

661

662

663

664

665 **References**

666

667 1. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, Hosein Z, Padda
668 I, Mangat J, Altaf M. 2020. Comorbidity and its Impact on Patients with COVID-19.
669 SN Compr Clin Med 2:1069–1076.

670 2. Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, McNeal T, Ghamande S,
671 Douin DJ, Talbot HK, Casey JD, Mohr NM, Zepeski A, Shapiro NI, Gibbs KW,
672 Files DC, Hager DN, Shehu A, Prekker ME, Erickson HL, Exline MC, Gong MN,
673 Mohamed A, Henning DJ, Steingrub JS, Peltan ID, Brown SM, Martin ET, Monto
674 AS, Khan A, Hough CL, Busse LW, ten Lohuis CC, Duggal A, Wilson JG, Gordon
675 AJ, Qadir N, Chang SY, Mallow C, Rivas C, Babcock HM, Kwon JH, Halasa N,
676 Chappell JD, Luring AS, Grijalva CG, Rice TW, Jones ID, Stubblefield WB,
677 Baughman A, Womack KN, Rhoads JP, Lindsell CJ, Hart KW, Zhu Y, Olson SM,
678 Kobayashi M, Verani JR, Patel MM, Influenza and Other Viruses in the Acutely Ill
679 (IVY) Network. 2021. Association Between mRNA Vaccination and COVID-19
680 Hospitalization and Disease Severity. JAMA 326:2043–2054.

681 3. Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, Li F, Xu Q, Zhang Y, Xu S, Song Z, Zeng
682 Y, Shen Y, Shi Y, Zhu T, Lu H. 2020. Clinical progression of patients with COVID-
683 19 in Shanghai, China. J Infect 80:e1–e6.

684 4. Mokhtari T, Hassani F, Ghaffari N, Ebrahimi B, Yarahmadi A, Hassanzadeh G.
685 2020. COVID-19 and multiorgan failure: A narrative review on potential
686 mechanisms. J Mol Histol 51:613–628.

- 687 5. Griffith DM, Sharma G, Holliday CS, Enyia OK, Valliere M, Semlow AR, Stewart EC,
688 Blumenthal RS. 2020. Men and COVID-19: A Biopsychosocial Approach to
689 Understanding Sex Differences in Mortality and Recommendations for Practice
690 and Policy Interventions. *Prev Chronic Dis* 17:E63.
- 691 6. He Y, Wang J, Ren J, Zhao Y, Chen J, Chen X. 2021. Effect of COVID-19 on Male
692 Reproductive System – A Systematic Review. *Frontiers in Endocrinology* 12.
- 693 7. Ma X, Guan C, Chen R, Wang Y, Feng S, Wang R, Qu G, Zhao S, Wang F, Wang
694 X, Zhang D, Liu L, Liao A, Yuan S. 2021. Pathological and molecular
695 examinations of postmortem testis biopsies reveal SARS-CoV-2 infection in the
696 testis and spermatogenesis damage in COVID-19 patients. 2. *Cell Mol Immunol*
697 18:487–489.
- 698 8. Duarte-Neto AN, Teixeira TA, Caldini EG, Kanamura CT, Gomes-Gouvêa MS, Dos
699 Santos ABG, Monteiro RAA, Pinho JRR, Mauad T, da Silva LFF, Saldiva PHN,
700 Dolhnikoff M, Leite KRM, Hallak J. 2022. Testicular pathology in fatal COVID-19:
701 A descriptive autopsy study. *Andrology* 10:13–23.
- 702 9. Rastrelli G, Di Stasi V, Inglese F, Beccaria M, Garuti M, Di Costanzo D, Spreafico F,
703 Greco GF, Cervi G, Pecoriello A, Magini A, Todisco T, Cipriani S, Maseroli E,
704 Corona G, Salonia A, Lenzi A, Maggi M, De Donno G, Vignozzi L. 2021. Low
705 testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia
706 patients. *Andrology* 9:88–98.

- 707 10. Schroeder M, Schaumburg B, Müller Z, Parplys A, Jarczak D, Nierhaus A, Kloetgen
708 A, Schneider B, Peschka M, Stoll F, Bai T, Jacobsen H, Zickler M, Stanelle-
709 Bertram S, Heer G de, Renné T, Meinhardt A, Heeren J, Aberle J, McHardy AC,
710 Schlüter H, Hiller J, Peine S, Kreienbrock L, Klingel K, Kluge S, Gabriel G. 2020.
711 Sex hormone and metabolic dysregulations are associated with critical illness in
712 male Covid-19 patients. medRxiv <https://doi.org/10.1101/2020.05.07.20073817>.
- 713 11. Guo L, Zhao S, Li W, Wang Y, Li L, Jiang S, Ren W, Yuan Q, Zhang F, Kong F, Lei
714 J, Yuan M. 2021. Absence of SARS-CoV-2 in semen of a COVID-19 patient
715 cohort. *Andrology* 9:42–47.
- 716 12. Holtmann N, Edimiris P, Andree M, Doehmen C, Baston-Buest D, Adams O,
717 Kruessel J-S, Bielfeld AP. 2020. Assessment of SARS-CoV-2 in human semen-a
718 cohort study. *Fertil Steril* 114:233–238.
- 719 13. Clinical Characteristics and Results of Semen Tests Among Men With Coronavirus
720 Disease 2019 | Global Health | JAMA Network Open | JAMA Network.
721 <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765654>. Retrieved
722 19 April 2022.
- 723 14. Pesaresi M, Pirani F, Tagliabracci A, Valsecchi M, Procopio AD, Busardò FP,
724 Graciotti L. 2020. SARS-CoV-2 identification in lungs, heart and kidney specimens
725 by transmission and scanning electron microscopy. *Eur Rev Med Pharmacol Sci*
726 24:5186–5188.

- 727 15. Martin-Cardona A, Lloreta Trull J, Albero-González R, Paraira Beser M, Andújar X,
728 Ruiz-Ramirez P, Tur-Martínez J, Ferrer C, De Marcos Izquierdo JA, Pérez-
729 Madrigal A, Goiburú González L, Espinós Perez J, Esteve M. 2021. SARS-CoV-2
730 identified by transmission electron microscopy in lymphoproliferative and
731 ischaemic intestinal lesions of COVID-19 patients with acute abdominal pain: two
732 case reports. *BMC Gastroenterology* 21:334.
- 733 16. Paniz-Mondolfi A, Bryce C, Grimes Z, Gordon RE, Reidy J, Lednicky J, Sordillo
734 EM, Fowkes M. 2020. Central nervous system involvement by severe acute
735 respiratory syndrome coronavirus-2 (SARS-CoV-2). *Journal of Medical Virology*
736 92:699–702.
- 737 17. Plescia CB, David EA, Patra D, Sengupta R, Amiar S, Su Y, Stahelin RV. 2021.
738 SARS-CoV-2 viral budding and entry can be modeled using BSL-2 level virus-like
739 particles. *Journal of Biological Chemistry* 296:100103.
- 740 18. Le Hingrat Q, Visseaux B, Laouenan C, Tubiana S, Bouadma L, Yazdanpanah Y,
741 Duval X, Burdet C, Ichou H, Damond F, Bertine M, Benmalek N, Choquet C,
742 Timsit J-F, Ghosn J, Charpentier C, Descamps D, Houhou-Fidouh N, Diallo A, Le
743 Mestre S, Mercier N, Paul C, Petrov-Sanchez V, Malvy D, Chirouze C, Andrejak
744 C, Dubos F, Rossignol P, Picone O, Bompard F, Gigante T, Gilg M, Rossignol B,
745 Levy-Marchal C, Beluze M, Hulot JS, Bachelet D, Bhavsar K, Bouadma L, Chair
746 A, Couffignal C, Da Silveira C, Debray MP, Descamps D, Duval X, Eloy P,
747 Esposito-Farese M, Ettalhaoui N, Gault N, Ghosn J, Gorenne I, Hoffmann I, Kafif
748 O, Kali S, Khalil A, Laouénan C, Laribi S, Le M, Le Hingrat Q, Lescure F-X, Lucet

749 JC, Mentré F, Mullaert J, Peiffer-Smadja N, Peytavin G, Roy C, Schneider M,
750 Mohammed NS, Tagherset L, Tardivon C, Tellier MC, Timsit J-F, Trioux T,
751 Tubiana S, Visseaux B, Vanel N, Basmaci R, Angoulvant F, Kaguelidou F, Pages
752 J, Tual C, Veislinger A, Couffin-Cardiergues S, Esperou H, Houas I, Jaafoura S,
753 Papadopoulos A, Coelho A, Diouf A, Hoctin A, Mambert M, Bouscambert M,
754 Gaymard A, Lina B, Rosa-Calatrava M, Terrier O, Benkerrou D, Dorival C,
755 Meziane A, Téoulé F, Guedj J, Le Nagard H, Lingas G, Neant N, Abel L,
756 Desvallée M, Khan C, Deplanque D, Yazdanpanah Y, Behilill S, Enouf V,
757 Mouquet H, Van Der Werf S, Cervantes-Gonzalez M, D'ortenzio E, Puéchal O,
758 Semaille C, Noret M, Etienne M, Levy Y, Wiedemann A, Duval X, Burdet C, Duval
759 X, Lina B, Tubiana S, Van Der Werf S, Abad F, Abry D, Alavoine L, Allain J-S,
760 Amiel-Taieb K, Audoin P, Augustin S, Ayala S, Bansard H, Bertholon F, Boissel N,
761 Botelho-Nevers E, Bouiller K, Bourgeon M, Boutrou M, Brick L, Bruneau L,
762 Caumes E, Chabouis A, Chan Thien E, Chirouze C, Coignard B, Costa Y,
763 Costenoble V, Cour S, Cracowski C, Cracowski J-L, Deplanque D, Dequand S,
764 Desille-Dugast M, Desmarets M, Detoc M, Dewitte M, Djossou F, Ecobichon J-L,
765 Elrezzi E, Faurous W, Fortuna V, Fouchard J, Gantier E, Gautier C, Gerardin P,
766 Gerset S, Gilbert M, Gissot V, Guillemain F, Hartard C, Hazevis B, Hocquet D,
767 Hodaj E, Ilic-Habensus E, A. J, Jeulin H, Kane M, Kasprzyk E, Kikoine J, Laine F,
768 Laviolle B, Lebeaux D, Leclercq A, Ledru E, Lefevre B, Legoas C, Legrand A,
769 Legrand K, Lehacaut J, Lehur C, Lemouche D, Lepiller Q, Lepuil S, Letienne E,
770 Lucarelli A, Lucet J-C, Madeline I, Maillot A, Malapate C, Malvy D, Mandic M,
771 Marty-Quinternet S, Meghadecha M, Mergeay-Fabre M, Mespoulhe P, Meunier A,

- 772 Migaud M-C, Motiejunaite J, Gay N, Nguyen D, Oubbea S, Pagadoy M, Paris A,
773 Paris C, Payet C, Peiffer-Smadja N, Perez L, Perreau P, Pierrez N, Pistone T,
774 Postolache A, Rasoamanana P, Reminiac C, Rexah J, Roche-Gouanvic E,
775 Rousseau A, Schoemaeker B, Simon S, Soler C, Somers S, Sow K, Tardy B,
776 Terzian Z, Thy M, Tournier A, Tyrode S, Vauchy C, Verdon R, Vernet P, Vignali V,
777 Waucquier N, Burdet C, Do Thi Thu H, Laouénan C, Mentre F, Pauline M,
778 Tubiana S, Dechanet A, Letrou S, Quintin C, Frezouls W, Le Hingrat Q, Houhou
779 N, Damond F, Descamps D, Charpentier C, Visseaux B, Vabret A, Lina B,
780 Bouscambert M, Van Der Werf S, Behillil S, Gaillanne L, Benmalek N, Attia M,
781 Barbet M, Demeret C, Rose T, Petres S, Escriou N, Barbet M, Petres S, Escriou
782 N, Goyard S, Kafif O, Piquard V, Tubiana S, Coignard B, Mailles A, Simondon A,
783 Dreyere M, Morel B, Vesval T, Inserm, Amat K, Ammour D, Aqourras K, Couffin-
784 Cadiergues S, Delmas C, Desan V, Doute J-M, Esperou H, Hendou S, Kouakam
785 C, Le Meut G, Lemestre S, Leturque N, Marcoul E, Nguiefang S, Roufai L, Laurent
786 A, Caillat-Zucman S. 2021. Detection of SARS-CoV-2 N-antigen in blood during
787 acute COVID-19 provides a sensitive new marker and new testing alternatives.
788 *Clinical Microbiology and Infection* 27:789.e1-789.e5.
- 789 19. Wang X, Lam J-Y, Wong W-M, Yuen C-K, Cai J-P, Au SW-N, Chan JF-W, To
790 KKW, Kok K-H, Yuen K-Y. 2020. Accurate Diagnosis of COVID-19 by a Novel
791 Immunogenic Secreted SARS-CoV-2 orf8 Protein. *mBio* 11:e02431-20.
- 792 20. Barhoumi T, Alghanem B, Shaibah H, Mansour FA, Alamri HS, Akiel MA, Alroqi F,
793 Boudjelal M. 2021. SARS-CoV-2 Coronavirus Spike Protein-Induced Apoptosis,
794 Inflammatory, and Oxidative Stress Responses in THP-1-Like-Macrophages:

- 795 Potential Role of Angiotensin-Converting Enzyme Inhibitor (Perindopril). *Frontiers*
796 *in Immunology* 12.
- 797 21. Karwaciak I, Sałkowska A, Karaś K, Dastyh J, Ratajewski M. 2021. Nucleocapsid
798 and Spike Proteins of the Coronavirus SARS-CoV-2 Induce IL6 in Monocytes and
799 Macrophages-Potential Implications for Cytokine Storm Syndrome. *Vaccines*
800 (Basel) 9:54.
- 801 22. Xia B, Shen X, He Y, Pan X, Liu F-L, Wang Y, Yang F, Fang S, Wu Y, Duan Z, Zuo
802 X, Xie Z, Jiang X, Xu L, Chi H, Li S, Meng Q, Zhou H, Zhou Y, Cheng X, Xin X, Jin
803 L, Zhang H-L, Yu D-D, Li M-H, Feng X-L, Chen J, Jiang H, Xiao G, Zheng Y-T,
804 Zhang L-K, Shen J, Li J, Gao Z. 2021. SARS-CoV-2 envelope protein causes
805 acute respiratory distress syndrome (ARDS)-like pathological damages and
806 constitutes an antiviral target. *Cell Res* 31:847–860.
- 807 23. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. 2020. The COVID-19
808 Cytokine Storm; What We Know So Far. *Frontiers in Immunology* 11.
- 809 24. Leung PS, Sernia C. 2003. The renin-angiotensin system and male reproduction:
810 new functions for old hormones. *J Mol Endocrinol* 30:263–270.
- 811 25. Pan P-P, Zhan Q-T, Le F, Zheng Y-M, Jin F. 2013. Angiotensin-converting
812 enzymes play a dominant role in fertility. *Int J Mol Sci* 14:21071–21086.
- 813 26. Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. 2020. Single-Cell RNA
814 Expression Profiling of ACE2, the Receptor of SARS-CoV-2. *Am J Respir Crit*
815 *Care Med* 202:756–759.

- 816 27. Liu X, Chen Y, Tang W, Zhang L, Chen W, Yan Z, Yuan P, Yang M, Kong S, Yan
817 L, Qiao J. 2020. Single-cell transcriptome analysis of the novel coronavirus
818 (SARS-CoV-2) associated gene ACE2 expression in normal and non-obstructive
819 azoospermia (NOA) human male testes. *Sci China Life Sci* 63:1006–1015.
- 820 28. Wang Z, Xu X. 2020. scRNA-seq Profiling of Human Testes Reveals the Presence
821 of the ACE2 Receptor, A Target for SARS-CoV-2 Infection in Spermatogonia,
822 Leydig and Sertoli Cells. *Cells* 9:920.
- 823 29. Strange DP, Jiyarom B, Pourhabibi Zarandi N, Xie X, Baker C, Sadri-Ardekani H,
824 Shi P-Y, Verma S. 2019. Axl Promotes Zika Virus Entry and Modulates the
825 Antiviral State of Human Sertoli Cells. *mBio* 10:e01372-19.
- 826 30. Pendergraft SS, Sadri-Ardekani H, Atala A, Bishop CE. 2017. Three-dimensional
827 testicular organoid: a novel tool for the study of human spermatogenesis and
828 gonadotoxicity in vitro. *Biol Reprod* 96:720–732.
- 829 31. Strange DP, Zarandi NP, Trivedi G, Atala A, Bishop CE, Sadri-Ardekani H, Verma
830 S. 2018. Human testicular organoid system as a novel tool to study Zika virus
831 pathogenesis. *Emerg Microbes Infect* 7:82.
- 832 32. Sadri-Ardekani H, Mizrak SC, van Daalen SKM, Korver CM, Roepers-Gajadien HL,
833 Koruji M, Hovingh S, de Reijke TM, de la Rosette JJMCH, van der Veen F, de
834 Rooij DG, Repping S, van Pelt AMM. 2009. Propagation of human spermatogonial
835 stem cells in vitro. *JAMA* 302:2127–2134.

- 836 33. Kumar M, Roe K, Orillo B, Muruve DA, Nerurkar VR, Gale M, Verma S. 2013.
837 Inflammasome adaptor protein Apoptosis-associated speck-like protein containing
838 CARD (ASC) is critical for the immune response and survival in west Nile virus
839 encephalitis. *J Virol* 87:3655–3667.
- 840 34. Etievant S, Bal A, Escuret V, Brengel-Pesce K, Bouscambert M, Cheynet V,
841 Generenaz L, Oriol G, Destras G, Billaud G, Josset L, Frobert E, Morfin F,
842 Gaymard A. 2020. Performance Assessment of SARS-CoV-2 PCR Assays
843 Developed by WHO Referral Laboratories. *J Clin Med* 9:1871.
- 844 35. Mulay A, Konda B, Garcia G, Yao C, Beil S, Sen C, Purkayastha A, Kolls JK,
845 Pociask DA, Pessina P, de Aja JS, Garcia-de-Alba C, Kim CF, Gomperts B,
846 Arumugaswami V, Stripp BR. 2020. SARS-CoV-2 infection of primary human lung
847 epithelium for COVID-19 modeling and drug discovery. *bioRxiv*
848 2020.06.29.174623.
- 849 36. Strange DP, Jiyarom B, Sadri-Ardekani H, Cazares LH, Kenny TA, Ward MD,
850 Verma S. 2021. Paracrine IFN Response Limits ZIKV Infection in Human Sertoli
851 Cells. *Frontiers in Microbiology* 12.
- 852 37. Kumar M, Verma S, Nerurkar VR. 2010. Pro-inflammatory cytokines derived from
853 West Nile virus (WNV)-infected SK-N-SH cells mediate neuroinflammatory
854 markers and neuronal death. *J Neuroinflammation* 7:73.
- 855 38. Maison DP, Nerurkar VR. 2021. Research Methodology to Define the Introduction
856 of the SARS-CoV-2 B.1.429 Variant in Hawaii. *Res Sq* rs.3.rs-378702.

- 857 39. Kumar M, Roe K, Nerurkar PV, Namekar M, Orillo B, Verma S, Nerurkar VR. 2012.
858 Impaired virus clearance, compromised immune response and increased mortality
859 in type 2 diabetic mice infected with West Nile virus. *PLoS One* 7:e44682.
- 860 40. Verma S, Saksena S, Sadri-Ardekani H. 2020. ACE2 receptor expression in testes:
861 implications in coronavirus disease 2019 pathogenesis†. *Biology of Reproduction*
862 103:449–451.
- 863 41. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S,
864 Schiergens TS, Herrler G, Wu N-H, Nitsche A, Müller MA, Drosten C, Pöhlmann
865 S. 2020. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is
866 Blocked by a Clinically Proven Protease Inhibitor. *Cell* 181:271-280.e8.
- 867 42. Kim Y, Jang G, Lee D, Kim N, Seon JW, Kim Y, Lee C. 2022. Trypsin enhances
868 SARS-CoV-2 infection by facilitating viral entry. *Arch Virol* 167:441–458.
- 869 43. Fajgenbaum DC, June CH. 2020. Cytokine Storm. *New England Journal of*
870 *Medicine* 383:2255–2273.
- 871 44. Ahmadian E, Hosseiniyan Khatibi SM, Razi Soofiyani S, Abediazar S, Shoja MM,
872 Ardalan M, Zununi Vahed S. 2020. Covid-19 and kidney injury: Pathophysiology
873 and molecular mechanisms. *Rev Med Virol* e2176.
- 874 45. Legrand M, Bell S, Forni L, Joannidis M, Koyner JL, Liu K, Cantaluppi V. 2021.
875 Pathophysiology of COVID-19-associated acute kidney injury. 11. *Nat Rev*
876 *Nephrol* 17:751–764.

- 877 46. Tang N, Li D, Wang X, Sun Z. 2020. Abnormal coagulation parameters are
878 associated with poor prognosis in patients with novel coronavirus pneumonia. *J*
879 *Thromb Haemost* 18:844–847.
- 880 47. Geng Y-J, Wei Z-Y, Qian H-Y, Huang J, Lodato R, Castriotta RJ. 2020.
881 Pathophysiological characteristics and therapeutic approaches for pulmonary
882 injury and cardiovascular complications of coronavirus disease 2019. *Cardiovasc*
883 *Pathol* 47:107228.
- 884 48. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus
885 Disease 2019 (COVID-19) | Cardiology | JAMA Cardiology | JAMA Network.
886 <https://jamanetwork.com/journals/jamacardiology/fullarticle/2763845>. Retrieved 7
887 February 2022.
- 888 49. Pensato U, Muccioli L, Cani I, Janigro D, Zinzani PL, Guarino M, Cortelli P, Bisulli
889 F. 2021. Brain dysfunction in COVID-19 and CAR-T therapy: cytokine storm-
890 associated encephalopathy. *Ann Clin Transl Neurol* 8:968–979.
- 891 50. Frontiers | Ebola Virus Glycoprotein Induces an Innate Immune Response In vivo
892 via TLR4 | Microbiology.
893 <https://www.frontiersin.org/articles/10.3389/fmicb.2017.01571/full>. Retrieved 11
894 February 2022.
- 895 51. Shed GP of Ebola Virus Triggers Immune Activation and Increased Vascular
896 Permeability.

- 897 <https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1004509>.
- 898 Retrieved 11 February 2022.
- 899 52. Modhiran N, Watterson D, Muller DA, Panetta AK, Sester DP, Liu L, Hume DA,
900 Stacey KJ, Young PR. 2015. Dengue virus NS1 protein activates cells via Toll-like
901 receptor 4 and disrupts endothelial cell monolayer integrity. *Sci Transl Med*
902 7:304ra142.
- 903 53. Chen J, Ng MM-L, Chu JJH. 2015. Activation of TLR2 and TLR6 by Dengue NS1
904 Protein and Its Implications in the Immunopathogenesis of Dengue Virus Infection.
905 *PLOS Pathogens* 11:e1005053.
- 906 54. McCray PB, Pewe L, Wohlford-Lenane C, Hickey M, Manzel L, Shi L, Netland J, Jia
907 HP, Halabi C, Sigmund CD, Meyerholz DK, Kirby P, Look DC, Perlman S. 2007.
908 Lethal infection of K18-hACE2 mice infected with severe acute respiratory
909 syndrome coronavirus. *J Virol* 81:813–821.
- 910 55. Oladunni FS, Park J-G, Pino PA, Gonzalez O, Akhter A, Allué-Guardia A, Olmo-
911 Fontánez A, Gautam S, Garcia-Vilanova A, Ye C, Chiem K, Headley C, Dwivedi
912 V, Parodi LM, Alfson KJ, Staples HM, Schami A, Garcia JI, Whigham A, Platt RN,
913 Gazi M, Martinez J, Chuba C, Earley S, Rodriguez OH, Mdaki SD, Kavelish KN,
914 Escalona R, Hallam CRA, Christie C, Patterson JL, Anderson TJC, Carrion R,
915 Dick EJ, Hall-Ursone S, Schlesinger LS, Alvarez X, Kaushal D, Giavedoni LD,
916 Turner J, Martinez-Sobrido L, Torrelles JB. 2020. Lethality of SARS-CoV-2
917 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. 1. *Nat*
918 *Commun* 11:6122.

- 919 56. Moreau GB, Burgess SL, Sturek JM, Donlan AN, Petri WA, Mann BJ. 2020.
920 Evaluation of K18-hACE2 Mice as a Model of SARS-CoV-2 Infection. *Am J Trop*
921 *Med Hyg* 103:1215–1219.
- 922 57. Arce VM, Costoya JA. 2021. SARS-CoV-2 infection in K18-ACE2 transgenic mice
923 replicates human pulmonary disease in COVID-19. 3. *Cell Mol Immunol* 18:513–
924 514.
- 925 58. Oladunni FS, Park J-G, Pino PA, Gonzalez O, Akhter A, Allué-Guardia A, Olmo-
926 Fontánez A, Gautam S, Garcia-Vilanova A, Ye C, Chiem K, Headley C, Dwivedi
927 V, Parodi LM, Alfson KJ, Staples HM, Schami A, Garcia JI, Whigham A, Platt RN,
928 Gazi M, Martinez J, Chuba C, Earley S, Rodriguez OH, Mdaki SD, Kavelish KN,
929 Escalona R, Hallam CRA, Christie C, Patterson JL, Anderson TJC, Carrion R,
930 Dick EJ, Hall-Ursone S, Schlesinger LS, Alvarez X, Kaushal D, Giavedoni LD,
931 Turner J, Martinez-Sobrido L, Torrelles JB. 2020. Lethality of SARS-CoV-2
932 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. 1. *Nat*
933 *Commun* 11:6122.
- 934 59. Winkler ES, Bailey AL, Kafai NM, Nair S, McCune BT, Yu J, Fox JM, Chen RE,
935 Earnest JT, Keeler SP, Ritter JH, Kang L-I, Dort S, Robichaud A, Head R,
936 Holtzman MJ, Diamond MS. 2020. SARS-CoV-2 infection of human ACE2-
937 transgenic mice causes severe lung inflammation and impaired function. 11. *Nat*
938 *Immunol* 21:1327–1335.
- 939 60. Yang M, Chen S, Huang B, Zhong J-M, Su H, Chen Y-J, Cao Q, Ma L, He J, Li X-
940 F, Li X, Zhou J-J, Fan J, Luo D-J, Chang X-N, Arkun K, Zhou M, Nie X. 2020.

- 941 Pathological Findings in the Testes of COVID-19 Patients: Clinical Implications.
942 Eur Urol Focus 6:1124–1129.
- 943 61. Duarte-Neto AN, Teixeira TA, Caldini EG, Kanamura CT, Gomes-Gouvêa MS, Dos
944 Santos ABG, Monteiro RAA, Pinho JRR, Mauad T, da Silva LFF, Saldiva PHN,
945 Dolhnikoff M, Leite KRM, Hallak J. 2022. Testicular pathology in fatal COVID-19:
946 A descriptive autopsy study. *Andrology* 10:13–23.
- 947 62. Schimmel L, Chew KY, Stocks CJ, Yordanov TE, Essebier P, Kulasinghe A,
948 Monkman J, dos Santos Miggiolaro AFR, Cooper C, de Noronha L, Schroder K,
949 Lagendijk AK, Labzin LI, Short KR, Gordon EJ. 2021. Endothelial cells are not
950 productively infected by SARS-CoV-2. *Clinical & Translational Immunology*
951 10:e1350.
- 952 63. Diao B, Wang C, Wang R, Feng Z, Zhang J, Yang H, Tan Y, Wang H, Wang C, Liu
953 L, Liu Y, Liu Y, Wang G, Yuan Z, Hou X, Ren L, Wu Y, Chen Y. 2021. Human
954 kidney is a target for novel severe acute respiratory syndrome coronavirus 2
955 infection. 1. *Nat Commun* 12:2506.
- 956 64. Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M, Leopoldi A,
957 Garreta E, Hurtado Del Pozo C, Prosper F, Romero JP, Wirnsberger G, Zhang H,
958 Slutsky AS, Conder R, Montserrat N, Mirazimi A, Penninger JM. 2020. Inhibition
959 of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade
960 Soluble Human ACE2. *Cell* 181:905-913.e7.

- 961 65. Li C, Ye Z, Zhang AJ-X, Chan JF-W, Song W, Liu F, Chen Y, Kwan MY-W, Lee
962 AC-Y, Zhao Y, Wong BH-Y, Yip CC-Y, Cai J-P, Lung DC, Sridhar S, Jin D, Chu H,
963 To KK-W, Yuen K-Y. 2022. Severe acute respiratory syndrome coronavirus 2
964 (SARS-CoV-2) infections by intranasal or testicular inoculation induces testicular
965 damage preventable by vaccination in golden Syrian hamsters. *Clinical Infectious
966 Diseases* ciac142.
- 967 66. Madden PJ, Thomas Y, Blair RV, Samer S, Doyle M, Midkiff CC, Doyle-Meyers LA,
968 Becker ME, Arif MS, McRaven MD, Simons LM, Carias AM, Martinelli E, Lorenzo-
969 Redondo R, Hultquist JF, Villinger FJ, Veazey RS, Hope TJ. 2022. An
970 immunoPET probe to SARS-CoV-2 reveals early infection of the male genital tract
971 in rhesus macaques. *bioRxiv* <https://doi.org/10.1101/2022.02.25.481974>.
- 972 67. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. 2020. The COVID-19
973 Cytokine Storm; What We Know So Far. *Frontiers in Immunology* 11.
- 974 68. Khan S, Shafiei MS, Longoria C, Schoggins JW, Savani RC, Zaki H. 2021. SARS-
975 CoV-2 spike protein induces inflammation via TLR2-dependent activation of the
976 NF- κ B pathway. *eLife* 10:e68563.
- 977 69. Xia B, Shen X, He Y, Pan X, Liu F-L, Wang Y, Yang F, Fang S, Wu Y, Duan Z, Zuo
978 X, Xie Z, Jiang X, Xu L, Chi H, Li S, Meng Q, Zhou H, Zhou Y, Cheng X, Xin X, Jin
979 L, Zhang H-L, Yu D-D, Li M-H, Feng X-L, Chen J, Jiang H, Xiao G, Zheng Y-T,
980 Zhang L-K, Shen J, Li J, Gao Z. 2021. SARS-CoV-2 envelope protein causes
981 acute respiratory distress syndrome (ARDS)-like pathological damages and
982 constitutes an antiviral target. *Cell Res* 31:847–860.

- 983 70. Chousterman BG, Swirski FK, Weber GF. 2017. Cytokine storm and sepsis
984 disease pathogenesis. *Semin Immunopathol* 39:517–528.
- 985 71. Reynard S, Journeaux A, Gloaguen E, Schaeffer J, Varet H, Pietrosemoli N, Mateo
986 M, Baillet N, Laouenan C, Raoul H, Mullaert J, Baize S. 2019. Immune
987 parameters and outcomes during Ebola virus disease. *JCI Insight* 4:125106.
- 988 72. Vanderheiden A, Ralfs P, Chirkova T, Upadhyay AA, Zimmerman MG, Bedoya S,
989 Aoued H, Tharp GM, Pellegrini KL, Manfredi C, Sorscher E, Mainou B, Lobby JL,
990 Kohlmeier JE, Lowen AC, Shi P-Y, Menachery VD, Anderson LJ, Grakoui A,
991 Bosinger SE, Suthar MS. 2020. Type I and Type III Interferons Restrict SARS-
992 CoV-2 Infection of Human Airway Epithelial Cultures. *Journal of Virology*
993 94:e00985-20.
- 994 73. Ryu G, Shin H-W. 2021. SARS-CoV-2 Infection of Airway Epithelial Cells. *Immune*
995 *Netw* 21:e3.
- 996 74. Ogata AF, Maley AM, Wu C, Gilboa T, Norman M, Lazarovits R, Mao C-P, Newton
997 G, Chang M, Nguyen K, Kamkaew M, Zhu Q, Gibson TE, Ryan ET, Charles RC,
998 Marasco WA, Walt DR. 2020. Ultra-Sensitive Serial Profiling of SARS-CoV-2
999 Antigens and Antibodies in Plasma to Understand Disease Progression in COVID-
1000 19 Patients with Severe Disease. *Clinical Chemistry* 66:1562–1572.
- 1001 75. George S, Pal AC, Gagnon J, Timalisina S, Singh P, Vydyam P, Munshi M, Chiu
1002 JE, Renard I, Harden CA, Ott IM, Watkins AE, Vogels CBF, Lu P, Tokuyama M,
1003 Venkataraman A, Casanovas-Massana A, Wyllie AL, Rao V, Campbell M,

- 1004 Farhadian SF, Grubaugh ND, Cruz CSD, Ko AI, Perez AZB, Akaho EH, Moledina
1005 DG, Testani J, John AR, Ledizet M, Mamoun CB, Team and the YI. 2021.
1006 Evidence for SARS-CoV-2 Spike Protein in the Urine of COVID-19 Patients.
1007 *Kidney360* 2:924–936.
- 1008 76. Zheng M, Karki R, Williams EP, Yang D, Fitzpatrick E, Vogel P, Jonsson CB,
1009 Kanneganti T-D. 2021. TLR2 senses the SARS-CoV-2 envelope protein to
1010 produce inflammatory cytokines. *Nat Immunol* 22:829–838.
- 1011 77. Mandala VS, McKay MJ, Shcherbakov AA, Dregni AJ, Kolocouris A, Hong M. 2020.
1012 Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane
1013 domain in lipid bilayers. *Nat Struct Mol Biol* 27:1202–1208.
- 1014 78. Yinda CK, Port JR, Bushmaker T, Offei Owusu I, Purushotham JN, Avanzato VA,
1015 Fischer RJ, Schulz JE, Holbrook MG, Hebner MJ, Rosenke R, Thomas T, Marzi
1016 A, Best SM, de Wit E, Shaia C, van Doremalen N, Munster VJ. 2021. K18-hACE2
1017 mice develop respiratory disease resembling severe COVID-19. *PLoS Pathog*
1018 17:e1009195.
- 1019 79. 2022. Testes found to viral reservoir for SARS-CoV-2 replication. News-
1020 Medical.net. [https://www.news-medical.net/news/20220213/Testes-found-to-viral-](https://www.news-medical.net/news/20220213/Testes-found-to-viral-reservoir-for-SARS-CoV-2-replication.aspx)
1021 [reservoir-for-SARS-CoV-2-replication.aspx](https://www.news-medical.net/news/20220213/Testes-found-to-viral-reservoir-for-SARS-CoV-2-replication.aspx). Retrieved 18 April 2022.
- 1022 80. Costa GMJ, Lacerda SMSN, Figueiredo AFA, Wnuk NT, Brener MRG, Campolina-
1023 Silva GH, Kauffmann-Zeh A, Pacifico LG, Versiani AF, Andrade LM, Antunes MM,
1024 Souza FR, Cassali GD, Caldeira-Brant AL, Chiarini-Garcia H, Costa VV, Fonseca

1025 FG da, Nogueira ML, Campos GRF, Kangussu LM, Martins EMN, Antonio LM,
1026 Bittar C, Rahal P, Aguiar RS, Mendes BP, Procópio MS, Furtado TP, Guimaraes
1027 YL, Menezes GB, Martinez-Marchal A, Brieno-Enriquez M, Orwig KE, Furtado
1028 MH. 2022. SARS-CoV-2 infects, replicates, elevates angiotensin II and activates
1029 immune cells in human testes. medRxiv
1030 <https://doi.org/10.1101/2022.02.05.22270327>.

1031




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5







Figure 6




Figure 7